Voyager Therapeutics and AbbVie, already partners developing gene therapies for Alzheimer’s disease, are now expanding their alliance to include Parkinson’s. AbbVie (NYSE: ABBV) is paying Cambridge, MA-based Voyager (NASDAQ: VYGR) $65 million up front under the new deal. Gene therapies use viruses to carry the genetic instructions into cells. The agreement calls for Voyager to […]

Here’s a roundup of recent news from Wisconsin’s high-tech industries: —Rockwell Automation (NYSE: ROK), the Milwaukee-based seller of hardware and software that enables industrial automation, is forming a joint venture with Houston-based Schlumberger (NYSE: SLB), a maker of products for drilling and other tasks in the oil and gas industry. The new venture, called Sensia, […]

The growing epidemic of the fatty liver disease known as NASH, which has no FDA-approved treatment, has led to a frenzied race among drug companies. This week, one company, Intercept Pharmaceuticals, solidified its lead. But how much will being first to the finish line mean when all is said and done? Intercept (NASDAQ: ICPT) reported […]

Raymond Sanchez has been appointed chief medical officer of Cerevel Therapeutics. Sanchez comes to Boston-based Cerevel from Otsuka Pharmaceutical Development and Commercialization, where he most recently served as senior vice president, global clinical development. During the last half of his 11-year tenure at Otsuka, he was also chief medical officer of Otsuka subsidiary Avanir Pharmaceuticals. […]